Nasalvicks (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa, it binds to alpha‑adrenergic receptors on the smooth muscle of nasal blood vessels, causing vasoconstriction. This reduces blood flow, decreases mucosal edema, and clears the nasal airway.

The appropriate dose of Nasalvicks is determined by a healthcare professional based on the patient’s age, condition, and response. Typically, adults and children over 12 years use one or two sprays per nostril every 4–6 hours, not exceeding three days of continuous use.

Safety of oxymetazoline in pregnancy or while breastfeeding has not been definitively established. Women who are pregnant, planning to become pregnant, or nursing should consult their healthcare provider before using Nasalvicks to weigh potential benefits against possible risks.

To place an order, submit an enquiry on the Nasalvicks product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nasalvicks contains oxymetazoline, which offers rapid onset of action and a duration of up to 12 hours, similar to other topical alpha‑adrenergic agents such as phenylephrine. Compared with oral decongestants, it provides localized effect with fewer systemic side effects, but it still requires careful use to avoid rebound congestion.

Store Nasalvicks at room temperature, below 25 °C, in the original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep it out of reach of children.

Nasalvicks is applied as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the recommended number of sprays while breathing in gently. The process is repeated in the other nostril if required.

Serious risks, though uncommon, include severe hypertension, tachycardia, arrhythmias, allergic reactions (rash, swelling, difficulty breathing), and nasal ulceration. These effects warrant immediate medical attention and discontinuation of the product.

Nasalvicks should be avoided by individuals with known hypersensitivity to oxymetazoline or any excipients, patients with severe hypertension, coronary artery disease, or those taking monoamine oxidase inhibitors. Children under six years of age should not use it unless specifically directed by a physician.